Building HOPE: operationalizing hybrid decentralized oncology clinical trials with community providers beyond traditional healthcare system networks
The Oncologist · 10.04.2026 · 31 (5)
DOI: 10.1093/oncolo/oyag118 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Oncologist, online erschienen am 31.03.2026. Verfasst von J Kaitlin Morrison und 20 weiteren Autor:innen. Beteiligte Einrichtung: Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, United States. Hauptthemen laut MEDLINE: Clinical Trials as Topic, Neoplasms, Health Personnel, Delivery of Health Care. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: FDA/HHS, Food and Drug Administration (FDA) Office of Minority Health and Health Equity (OMHHE) of the U.S. Department of Health and Human Services (HHS), NCATS NIH HHS.
Abstract (Originalsprache)
Background
Cancer clinical trials are essential to high-quality oncology care, yet regulatory and logistical barriers have concentrated trial activity at academic medical centers, limiting access for rural and underserved populations. In 2022, 75% of U.S. counties had no active cancer treatment trials. North Carolina (NC) exemplifies these disparities, where limited local trial options, long travel distances, and socioeconomic barriers hinder participation. Materials and methods To develop operational methodologies for hybrid decentralized clinical trials (hDCTs), the University of North Carolina Lineberger Comprehensive Cancer Center (LCCC) conducted an engagement initiative across nine community hospitals in NC without formal contractual research network agreements. 120 stakeholders—healthcare providers (HCPs), nurses, pharmacists, administrators, and advocates—shared insights that informed the co-development of adaptable workflows, including communication protocols, adverse event management strategies, and literacy-sensitive patient materials. Procedures were designed to align with local clinical practices and reduce burden on HCPs without requiring engagement from a regulatory standpoint.
Results
Visits revealed critical local resources, such as patient transportation, culturally tailored educational materials, and advocacy, that could facilitate hDCT participation. Key facilitators included motivated local champions, supportive leadership, and infrastructure for remote visits. Within 3 months, seven of nine locations initiated hDCT planning, five began patient referrals, and two enrolled patients. Early data show promising uptake and strong institutional commitment. Conclusions hDCTs are feasible in community settings beyond traditional healthcare networks and can expand trial access by reducing logistical and financial burdens. The LCCC model offers a scalable framework to promote equity in cancer research.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, United States.
- Department of Medicine, Division of Hematology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27514, United States.
- UNC Rex Cancer Center, Raleigh, NC 27607, United States.
- Department of Radiation Oncology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27514, United States.
- UNC Health Office of Clinical Research, Chapel Hill, NC 27599, United States.
- Department of Health Policy and Management, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, United States.
ORCID-Profile: J Kaitlin Morrison, Carrie Lee
Förderung
- FDA/HHS
- Food and Drug Administration (FDA) Office of Minority Health and Health Equity (OMHHE) of the U.S. Department of Health and Human Services (HHS)
- NCATS NIH HHS
- U.S. Government
- FDA/HHS and
- FDA HHS
- National Center for Advancing Translational Sciences (NCATS)
- NIH HHS
Zitieren
APA
Morrison, J. K., Kiefer, L. V., Camp, A., Moore, E., Laffan, M., Adams, B., Maccarone, J., Kelly, E., Knutsen, M., Scott, S., Robinson, R., Huamani-Bundy, J., Burns, N., Haines, M., Crecelius, E., Sud, S., Finch, K., Potter, J., Wheeler, S. B., …, & Lee, C. (2026). Building HOPE: operationalizing hybrid decentralized oncology clinical trials with community providers beyond traditional healthcare system networks. The Oncologist, 31(5). https://doi.org/10.1093/oncolo/oyag118
Vancouver
Morrison JK, Kiefer LV, Camp A, Moore E, Laffan M, Adams B, et al. Building HOPE: operationalizing hybrid decentralized oncology clinical trials with community providers beyond traditional healthcare system networks. The Oncologist. 2026;31(5). doi:10.1093/oncolo/oyag118
BibTeX
@article{Morrison2026,
author = {Morrison, J Kaitlin and Kiefer, Leila Valanejad and Camp, Allison and Moore, Erica and Laffan, Megan and Adams, Blair and Maccarone, Julianna and Kelly, Erin and Knutsen, Melissa and Scott, Shaw and Robinson, Ryan and Huamani-Bundy, Jessica and Burns, Nancy and Haines, Melissa and Crecelius, Erin and Sud, Shivani and Finch, Kerry and Potter, Jennifer and Wheeler, Stephanie B and Martin, Barbara Alvarez and Lee, Carrie},
title = {Building HOPE: operationalizing hybrid decentralized oncology clinical trials with community providers beyond traditional healthcare system networks},
journal = {The Oncologist},
year = {2026},
volume = {31},
number = {5},
doi = {10.1093/oncolo/oyag118}
}
EUVIMED